Neurolief Ltd.
8
0
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
2 terminated/withdrawn out of 8 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Role: lead
EEG Biomarker Study for Participants in the Neurolief "MOOD" Trial
Role: collaborator
Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine
Role: lead
The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Role: lead
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
Role: lead
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Role: lead
A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.
Role: lead
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain
Role: lead
All 8 trials loaded